B. Riley raised the firm’s price target on TG Therapeutics to $29 from $24 and keeps a Buy rating on the shares. The analyst sees a high likelihood of TG “screening in the basket of successful product launch stories” as Briumvi U.S. commercial execution “gets in high gear” over the course of the 2024-2025 timeframe.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on TGTX:
- TG Therapeutics price target lowered to $22 from $23 at JPMorgan
- TG Therapeutics price target raised to $39 from $37.50 at Ladenburg
- Biotech Alert: Searches spiking for these stocks today
- TG Therapeutics price target raised to $45 from $41 at H.C. Wainwright
- Unusually active option classes on open January 10th
